pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection
Merck KGaA, Darmstadt
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt is a pharma organization headquartered in Darmstadt, DE. Primary therapeutic focus areas include Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, So
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Frankfurter Str. 250, Darmstadt, 64293, DE
- Employees
- 7,364
- Programs
- 63
- Drugs
- 50
- Patents
- 0
M5049 low dose
Phase 2 · small molecule · Systemic Lupus Erythematosus
M5049 low dose for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Internal code MS200569_0048
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Systemic Lupus Erythematosus
- Status
- active
- Trials
- 1